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Stimulated parotid salivary flow rates were compared in elderly normotensive,
hypertensive, and controlled hypertensive African-Americans, the latter group
taking hydroehlorothiazide (HCTZ), The normotensive group eonsisted of 15
healthy unmedicated subjects with systolic blood pressures of less than 150 mm
Hg and diastolic pressures less than 90 mm Hg, The hypertensive group consisted
of 10 unmedieated subjects with systolic pressures greater than 160 mm Hg and
diastolic pressures greater than 100 mm Hg, The controlled hypertensive group
consisted of 20 subjects taking HCTZ (50 mg, daily) with controlled blood pressures
similar to the normotensive control group. Stimulated parotid salivary samples
were collected from each subjeet, A 2"A citrate solution applied to the dorsum
of the tongue was used for stimulation. The results showed no significant differ-
enees in stimulated parotid flow rates between normotensive and uncontrolled
hypertensive subjeets. However, the medicated, controlled hypertensive subjects
had a significant reduction of stimulated parotid salivary flow rates compared to
both the normotensive and hypertensive groups.
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The production of saliva by the major
and minor salivary glands is essential
for the maintenance and protection of
the hard and soft tissues of the oral
cavity and the inhibition of serious sys-
temic pathogens (1,2)
Although parotid salivary produc-
tion seems to be unchanged by age (3),
there are Pharmaceuticals commonly
used by the elderly whieh are thought
to influence parotid salivary seeretion
(4,5). Specifically, antihypertensive, di-
uretic, and antidepressant medications
commonly utilized by the elderly dimin-
ish salivary produetion (6-9),
The subjective complaint of mouth
dryness xerostomia is commonly associ-
ated with the elderly, especially among
individuals who have hypertension (10),
Several investigators have attributed
this symptom to the side effects result-
ing from the use of antihypertensive
medication (2, 7), Hydroehlorothiazide
(HCTZ), for example, has been shown
to decrease stimulated whole saliva (11,
12), Further information regarding the
effects of HCTZ on salivary function
could not be found in the literature.
In addition to the paucity of informa-
tion coneerning HCTZ and salivary
funetion, there is little information eon-
cerning salivary gland funetion in hy-
pertensive individuals prior to use of
antihypertensive medication, BEN-ARY-
HH et al, (13) reported higher un-
stimulated whole salivary flow rates in
normotensive as compared to hyperten-
sive patients prior to being treated with
Pindolol, RAHN et al. (14) in a similar
study, also found higher unstimulated
whole salivary flow rates in normoten-
sive individuals compared to mildly hy-
pertensive individuals prior to being
placed on propranolol medication.
Conversely, NIEDHRMBIER et al. (15)
found no differences in unstimulated
and stimulated whole salivary flow rates
in hypertensive subjects when compared
to a normotensive control group. There-
fore, there is no consensus on the influ-
ence of antihypertensive medication on
salivary gland flow rates, and no infor-
mation relevant to glandular secretions.
Since whole saliva, in addition to glan-
dular secretions, also contains food de-
bris, desquamated epithelial cells, spu-
tum, bacteria and their prodticts, it is
difficult to evaluate whole saliva and
draw conclusions about glandular func-
tion (16),
Accordingly, the purpose of this
study was to evaluate stimulated par-
otid flow rate, and parotid saliva for its
electrolyte constituents and the concen-
tration of total IgA in normotensive,
hypertensive, and HCTZ-treated indi-
viduals who were hypertensive prior to
pharmacological therapy. The individ-
uals in this study were all African-
Americans, a segment of society known




The subjects participating in the study
were from the Washington Village Med-
ical Center. They were all African-
Americans residing in the Southwest
section of Baltimore City, Maryland.
The participants were ambulatory pa-
tients seeking routine medical or dental
care at the center, and were of low
socio-economic class. Detailed demo-
graphic and social characteristics have
been reported previously (19),
Subjects were divided into three
groups depending on hypertensive
status (Table 1), The individuals in the
normotensive group (9 women, 6 men)
were healthy and were not taking any
prescription or non-prescription medi-
cation. The hypertensive group (2
women, 8 men) was otherwise healthy
and not taking any medication. The
HCTZ-medicated individuals (10 wo-
men, 10 men) were on HCTZ with a
potassium sparing component, spirono-
lactodone, and no other medication,
HCTZ is a commonly prescribed an-
tihypertensive used in the treatment of
hypertension to reduce the expanded in-
travascular volume, which is a common
cardiovascular clinical finding among
African-Americans (17). All medicated
individuals were on the same brand or
type of medication. The HCTZ tablets
were counted to ensure compliance with
the therapeutic regimen.
Blood pressure determinations
Blood pressure measurements were
taken on each person's right arm in a
sitting position with a Baumanometer
between 8 a,m, and 12 noon, Normoten-
sive patients were categorized (20) as
having blood pressures of less than 150
mm Hg systolic and less than 90 mm
Hg diastolic. Hypertensive individuals
were those individuals who had systolic
pressures greater than 160 mm Hg and
diastolic pressures greater than 100 mm
Hg, The hypertensive individuals in this
study were found to have undiagnosed
asymptomatic hypertension from rou-
tine hypertension screening. These indi-
viduals were immediately referred to the
facility's attending physician for diag-
nosis and treatment. After being diag-
nosed with hypertension by the at-
tending physician, the subjects were in-
structed to return to the center to
receive their medication the next morn-
ing. In the uncontrolled hypertensive
group stimulated parotid flow rates
were collected prior to the initiation of
medication.
The HCTZ group of individuals had
been controlled with 50 mg daily of
medication so that each person's systol-
ic blood pressure was less than 150 mm
Hg and the diastolic was less than 90
mm Hg. They had been on HCTZ thera-
py for at least two years.
Collection of saliva
Saliva was collected from the right par-
otid gland of all subjects between the
hours of 8 a.m. to 12 noon using the
Carlson-Crittenden Cup to control for
circadian variation (22), Subjects from
all three groups were equally distributed
with respect to time of collection. The
patients tested had not eaten, drank, or
performed oral hygiene for at least two
hours prior to collection of saliva, Sten-
son's duct was visualized and the cup
positioned over the orifice. Stimulated
saliva fiow was observed for a two min-
ute equilibrium period followed by a
two minute period of actual salivary col-
lection. A 2% citric acid solution was
applied to the dorsum of the tongue
every 30 seconds during the two minute
equilibrium and the two minute collec-
tion periods. Samples were collected in
pre-weighed plastic tubes and salivary
output was determitied gravimetrically
(23). After the samples were weighed.
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they were immediately frozen in liquid
nitrogen.
Laboratory analysis
Sodium and potassium concentrations
were measured by automated flame
photometry while calcium and chloride
levels were measured by automated
spectrophotometry. Total protein values
were obtained by spectrophotometry
and total IgA concentrations by radial
immunodiffusion. IgA secretion rates
were determined by multiplying the sali-
vary flow rate by the IgA concentration
(24). All samples were analyzed at the
same time to control for possible analyt-
ical variables (e.g. variance with assay
kits, instruments, and analyst).
Statistical analysis
The data analysis used the SAS Statisti-
cal Software Package on a mainframe
computer. Descriptive analyses were
performed on the three groups (Tables
1 & 2). Analysis of variance was used
to test for overall differences among
groups for the mean levels of salivary
fiow rates and salivary constituents. Be-
cause of the unbalanced design of our
study (i.e, unequal numbers of observa-
tions among the three groups), the
PROC GLM (25) was used for the anal-
yses. In the presence of significant over-
all group differences, paired compari-
sons were made to identify those partic-
ular groups that were significantly
different from one another. The signifi-
cance for these analyses was p<0.05.
Results
Initial analyses found no differences in
stimulated parotid flow rates between
normotensive individuals and their hy-
pertensive counterparts; however, both
groups had a higher stimulated parotid
fiow rate than the HCTZ-medicated
group, which was significant at the
p<0.02 and p<0.03 levels respectively
(Table 2), The normotensive and hyper-
tensive groups also exhibited higher so-
dium levels, but only that for the hyper-
tensive group was statistically signi-
ficant, p<0.01. The medicated group
displayed a higher potassium level than
the hypertensive group, p < 0.005. There
were no differences in chloride, calcium,
total protein, and total IgA concentra-
tions among the three groups. However,
the normotensive and hypertensive
groups showed higher total IgA secre-
tion rates than the HCTZ-medicated
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- Not statistically significant
group. This was significant at the
p<0.02 and the p<0.05 levels respec-
tively.
Discussion
The results of this study demonstrate
that the HCTZ-medicated African-
Americans had significantly lower stim-
ulated parotid fiow rates compared to
normotensive and hypertensive control
groups, as well as a corresponding lower
IgA secretion rate. It is important to
consider these findings in view of the
known mechanisms involved in salivary
fiuid secretion. Salivary fluid secretion
involves two major steps; 1) an acinar
stage yielding a primary saliva which is
isotonic to that of plasma and 2) the
transport of saliva through the duct sys-
tem whereby constituent concentrations
are altered, resulting in a final saliva
which is hypotonic with respect to plas-
ma (26), The primary saliva becomes
hypotonic due to the extensive ductal
reabsorption of Na"*" and Cl^, and the
modest secretion of K^ and HCOj
(27). Primary fltiid secretion depends on
several distinct transport molecules, in-
cluding the Ca^ "̂  activated Cr and/
or HCOj^ channel, the Na+/K + / C r
cotransporter, the Ca"* "̂  activated K*
channel, the Na* /H* exchanger (where
the enzyme carbonic anhydrase facili-
tates the intracellular conversion of CO,
to HCO, ) and Na+/K+ ATPase (27̂
28).
The specific nature of the chemical
interaction between the thiazide diuret-
ics and salivary transport molecules is
not known; however, the benzothiadia-
zides are known to have carbonic anhy-
drase inhibiting diuretic properties (21).
Indeed, HCTZ is a recognized carbonic
anhydrase inhibitor with an IC50 of
about 20 \xM (21). HCTZ has a molecu-
lar weight of 223. At a dosage of 50 mg
daily and an estimated cardiovascular
volume of approximately 6 liters, a se-
rum HCTZ concentration of approxi-
mately 29 nM is calculated, a value ap-
proximating its ICjo for carbonic anhy-
drase inhibition. This suggests a
possibility that the fiuid secretion inhi-
bition observed here with the usage of
HCTZ may be due to an inhibition of
the HCOj^-mediated component of sal-
ivary fiuid secretion (by blocking the
formation of intracellular HCO,^). This
would result in a reduction of salivary
secretion, but not a complete inhibition
because the Ch driven (Na+/K+/Cr^
cotransport) component would still be
functional and unaffected by HCTZ.
The lower salivary sodium concentra-
tion in the HCTZ medicated group
could possibly be simply a secondary
result of the decrease in the salivary fiow
rate. It is recognized that the [Na+] in
saliva is flow rate dependent. As the
salivary flow rate decreases, the sodium
concentration also decreases due to in-
creased sodium reabsorption in the
ductal system (29), It is also possible
that the reduced sodium level in the
medicated group is the overall result of
the renal effects of the HCTZ medica-
tion, which is designed to decrease sodi-
um retention and thereby reduce sys-
temic fiuid retention (21).
Similarly, the elevated potassium
level in the medicated group could be
the result of the decreased stimulated
parotid fiow rate. A decreased stim-
ulated parotid fiow rate would result
in moderately higher salivary potassium
levels due to increased rate of potassium
secretion by the duct cells. Further re-
search is obviously needed to determine
the exact mechanism(s) by which the
observed results occur.
The results of this study suggest that
in individuals with hypertension taking
HCTZ medication, a decreased stim-
ulated parotid fiow rate is secondary to
the effect of the medication rather than
the effect of the disease. The stimulated
parotid gland fiow rates in the HCTZ-
medicated group were lower (40%) than
in the normotensive and hypertensive
groups, but were still within the normal
ranges of saliva production as described
by Ship et al, (30). Although it has been
demonstrated that stimulated parotid
fiow rates undergo essentially no change
over time in healthy persons (3), it is
not known in what manner medication
and disease may infiuence salivary phys-
iology over time in an older adult (16).
Consequently, it may be prudent for the
oral health care practitioner to monitor
the oral condition of HCTZ-tnedicated
individtials of frequent intervals (31),
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